215 results about "Hypoglycemic drugs" patented technology

The invention provides application of polygonatum cyrtonema polysaccharide in preparation of medicines for treating ulcerative colitis or reducing blood glucose. A main chain of a sugar chain structure of the homogeneous polysaccharide PCP2 in polygonatum cyrtonema is mainly composed of-> 1)-beta-D-Fur-(2->,-> 1, 6)-beta-D-Fur-(2-> and-> 6)-alpha-D-Glcp-(1-> and beta-D-Fur-(2->), a side chain is mainly composed of beta-D-Fur-(2-> and-> 2)-beta-D-Fur-(6-> at a C-6 position of-> 1, 6)-beta-D-Fur-(2->), Fur represents furanose, Glcp represents glucopyranose, Glcp represents glucopyranose, and Glcp represents glucopyranose. The novel polysaccharide compound can relieve intestinal injury of mice, increase expression of tight nectin and mucoprotein, relieve oxidative stress reaction, promote production of short-chain fatty acid and improve composition of intestinal flora, and can be applied to the field of medicine as a medicine for treating ulcerative colitis. Meanwhile, the homogeneous polysaccharide PCP2 in polygonatum cyrtonema can significantly inhibit the activity of alpha-amylase and alpha-glucosidase, can also promote the ability of insulin resistance 3T3-L1 fat cells to uptake and consume glucose, shows a significant hypoglycemic effect, and has a good development prospect in the aspect of preparation of hypoglycemic drugs.

The invention provides homogenized pitaya polysaccharide as well as a preparation method and application thereof, and belongs to the technical field of polysaccharide extraction and purification. The homogenized pitaya polysaccharide is a polysaccharide of which the monosaccharide is composed of mannose, glucosamine hydrochloride, rhamnose, glucuronic acid, galacturonic acid, glucose, galactose and arabinose, the relative molecular weight is 8.08 * 10 < 4 > Da, and the corresponding molar ratio is (0.181): (0.250): (16.544): (12.762): (3.793): (0.739): (51.014): (14.716). The invention further provides a preparation method of the homogenized pitaya polysaccharide and application of the homogenized pitaya polysaccharide in preparation of lipid-lowering and sugar-lowering drugs. The homogenized pitaya polysaccharide disclosed by the invention has an obvious lipid-lowering and blood-glucose-reducing effect, is from a natural product, so that the homogenized pitaya polysaccharide has no toxic or side effect and can be used for preparing lipid-lowering and blood-glucose-reducing medicines.

The name of the invention is application of Peniazathilone A as an alpha-glucosidase inhibitor and a preparation method of the Peniazathilone A. The invention belongs to the technical field of medicines, and relates to application of an azone compound as the alpha-glucosidase inhibitor. The compound has the following structure: # imgabs0 #. The compound Peniazathilone A is obtained by extracting, separating and purifying an ethyl acetate extract phase of a fermented product of Penicillium sp from soil, and the alpha-glucosidase inhibition activity of the compound is evaluated by adopting a pNPG method. Experimental results show that the IC50 value of the compound Peniazathilone A is 86.8 [mu] M (the IC50 value of a positive control acarbose is 5.97 mM), and the inhibition rate reaches 92.4% when the concentration of the compound is 0.466 mM. The compound has obvious activity of inhibiting alpha-glucosidase, is expected to be developed into a novel hypoglycemic drug, and has potential medical and health-care values.

The invention relates to a plant lactobacillus with hypoglycemic ability, and an application, a product and a method thereof, and belongs to the technical field of microorganisms. The invention provides a lactobacillus plantarum strain Lp116 with the capability of reducing blood sugar, and the preservation number of the lactobacillus plantarum strain Lp116 is CCTCC (China Center for Type Culture Collection) NO: M 20241784. The invention also provides an application of the strain Lp116 in preparation of hypoglycemic drugs or health-care foods with an auxiliary hypoglycemic function or bacteriostatic agents or non-treatment-destination bacteriostasis, and a product and a method based on the strain Lp116. The strain Lp116 disclosed by the invention has a relatively strong inhibition effect on escherichia coli, staphylococcus aureus, salmonella, streptococcus pharyngobuccal inflammation and streptococcus pseudopneumoniae, and can effectively achieve the effects of reducing blood sugar and regulating intestinal flora.

The invention discloses a preparation method of magnesium acetyltaurate and application of the magnesium acetyltaurate in preparation of hypoglycemic drugs or health care products, research finds that magnesium acetyltaurate has an obvious hypoglycemic effect, and results of repeated verification of mouse sugar tolerance animal experiments of single-time administration and multiple-time administration of magnesium acetyltaurate prove that the magnesium acetyltaurate has the obvious hypoglycemic effect. The magnesium acetyltaurate can reduce the blood sugar level of the mouse, basically has no influence on the weight of the mouse, can be used as a medicine for reducing the blood sugar, and has good development and application prospects. The preparation method disclosed by the invention is simple to operate and low in cost, and large-scale preparation of magnesium acetyltaurate can be realized.

The invention relates to ackermania muciniphila Akk21 with hypoglycemic capacity and application, a product and a method thereof, and belongs to the technical field of microorganisms. The invention provides an ackermania muciniphila strain Akk21 with a blood sugar reducing capability. The preservation number of the ackermania muciniphila strain Akk21 is CCTCC (China Center for Type Culture Collection) NO: M 20242779. The invention also provides hypoglycemic drugs, functional food for promoting lead excretion, health care products and a method for preventing and treating lead / arsenic pollution based on the strain Akk21. The Ackermania muciniphila Akk21 has excellent lead and arsenic tolerance and hypoglycemic capacity, can effectively reduce the blood lipid level of mice with type II diabetes, has a remarkable reduction effect on inflammation of the whole body of the mice, and can remarkably reduce the number of harmful flora in the intestinal tract by increasing the abundance of effective flora in the intestinal tract, so that the content of the harmful flora in the intestinal tract is reduced, and the content of the harmful flora in the intestinal tract is reduced. The species diversity and abundance of intestinal flora are improved.

An α-amylase inhibitory peptide. The peptide comprises amino acid sequences of eight adjacent amino acids X1, X2, X3, X4, X5, X6, X7, and X8, wherein each amino acid of the peptide is independently selected from a D-amino acid or an L-amino acid, and at least one of X2, X4, and X6 is W. The peptide has α-amylase inhibitory activity, has the effects of losing weight and lowering blood sugar, and can be used for preparing α-amylase inhibitors, weight-losing drugs, hypoglycemic drugs, or foods, health-care products or drugs for preventing or treating obesity-related diseases.

The invention provides camel milk active peptide and application thereof in preparation of drugs and edible products for treating and / or preventing diabetes mellitus. Two polypeptide compounds are obtained from papain enzymolysis products of fresh camel milk. Bioactivity evaluation shows that the polypeptide compound has remarkable protein tyrosine phospholipase 1B (PTP1B) inhibitory activity, can enhance insulin receptor sensitivity and promote hepatocyte glucose uptake, has patent medicine potential in the aspect of treating type II diabetes, and can be used for preparing medicines for treating type II diabetes. And a new material basis is provided for developing innovative medicines for treating type II diabetes and developing innovative PTP1B inhibitor hypoglycemic medicines.

The invention discloses a conductive microneedle patch for diabetes wound healing and a preparation method and application thereof, and belongs to the technical field of biomedical materials. The conductive microneedle patch is of a nesting doll type double-layer structure formed by an inner layer and an outer layer, microneedles on the inner layer are constructed through a methacrylic anhydride modified gelatin template pouring method, and polyvinyl alcohol microneedles on the top layer are formed by the outer layer through a lining-template pouring method. Wherein the microneedle patch has remarkable conductivity and antibacterial property due to a conductive nano-material silver nanowire in the inner-layer microneedle, and the outer-layer microneedle is loaded with a hypoglycemic drug and a natural humectant betaine, so that the properties of moisturizing and continuously releasing drugs are achieved. The obtained microneedle patch can keep a wound moist environment and adjust a diabetes wound inflammation microenvironment, cell and blood vessel growth is promoted through exogenous electrical stimulation, and rapid healing of a diabetes wound can be effectively achieved by releasing a hypoglycemic drug.

The invention discloses a self-crosslinking hydrogel with a tertiary amine group and preparation and application thereof, and belongs to the field of biomedical polymer materials, the self-crosslinking hydrogel comprises aminophenylboronic acid modified oxidized glucan, tertiary amine compound modified oxidized glucan and a solvent medium; the preparation method comprises the following steps: dissolving amino phenylboronic acid modified oxidized dextran and tertiary amine compound modified oxidized dextran in a solvent medium, mixing, standing for a certain time, and carrying out self-crosslinking to obtain the self-crosslinking hydrogel with tertiary amine groups. A cross-linking point (phenylboronic acid) of the gel network is a response unit of glucose. In addition, the hydrogel can effectively avoid uncontrollable drug release caused by non-responsive factors, and the response release efficiency of the drug is improved; by loading the hypoglycemic drug insulin to be applied to the treatment research process of diabetes, the occurrence of hypoglycemia can be avoided, and meanwhile, the possibility is provided for realizing intelligent controlled release of insulin through blood glucose response.

The invention discloses a BimBH3 analogue containing D-type amino acid and N-terminal fatty acid acylation, a preparation method of the BimBH3 analogue and application of the BimBH3 analogue as a PTPN1 inhibitor to development of hypoglycemic drugs. The structural general formula of the novel BimBH3 mimic peptide analogue is shown as a formula I: # imgabs0 #, wherein Raa2 is equal to D-His, D-Leu, D-Pro, D-Ser, D-Arg, D-Gln, D-Lys, D-Trp, D-Val, D-Tyr, D-Ala, Raa3 is equal to D-Gln, Raa7 is equal to D-Arg, and Raa8 is equal to D-Allo-Ile. The mimic peptide compound is derived from a core region of a Bim-BH3 structural domain, different D-type amino acid site-specific replacement modification and N-terminal conjugated hexadecanoic acid modification are adopted for amino acids at the second, third, seventh and eighth sites respectively, the BimBH3 mimic peptide modified by the D-type amino acid is more stable and has higher metabolic stability, and the target binding capacity and inhibitory activity of the BimBH3 mimic peptide can still be reserved or even improved. The BimBH3 mimic peptide compound shows an excellent PTPN1 inhibitor, the ability of resisting protease hydrolase and various digestive enzymes is also remarkably improved, and the BimBH3 mimic peptide compound has longer pharmacological action time and can play a potential long-acting hypoglycemic role through subcutaneous injection or oral administration. The compound is completely prepared by a polypeptide solid-phase synthesis method, and an obtained crude product is subjected to semi-preparative liquid chromatography purification and freeze-drying to obtain a target compound.

The invention belongs to the technical field of plant active peptides, and particularly relates to a red kidney bean hypoglycemic active peptide and application thereof. The amino acid sequences of the hypoglycemic active peptide are FFGGPAF, SAKPFFSGL and PPGHPFVTF. The invention further discloses a preparation method of the hypoglycemic active peptide. FF, SL and PF for short. The polypeptide is prepared through enzymolysis of red kidney bean protein, and the polypeptide is identified by utilizing ultrafiltration separation and LC-MS / MS (Liquid Chromatography-Mass Spectrometry / Mass Spectrometry); the hypoglycemic active peptides which are high in hypoglycemic effect, free of toxicity, carcinogenicity and sensitization and capable of being absorbed by human intestinal tracts are screened out through a bioinformatics method and molecular docking, then the screened hypoglycemic active peptides and alpha-glucosidase are subjected to molecular docking, and finally three hypoglycemic active peptides FF, SL and PF are screened out. The invention finds that the hypoglycemic active peptides FF, SL and PF have high inhibitory activity on alpha-glucosidase, can obviously promote glucose consumption of insulin resistance model cells, and can be used for preparing hypoglycemic drugs, food and health care products.

The invention relates to the technical field of microorganisms, in particular to lactobacillus rhamnosus ZKLGG0310, dendrobium officinale fermentation liquor of the lactobacillus rhamnosus ZKLGG0310 and application of the lactobacillus rhamnosus ZKLGG0310 to preparation of hypoglycemic drugs, the lactobacillus rhamnosus ZKLGG0310 is preserved in the China General Microbiological Culture Collection Center on May 13, 2024, the preservation address is No. 3, No.1 yard, Beichen West Road, Chaoyang District, Beijing, and the preservation number is CGMCC NO. The preservation number is CGMCC (China General Microbiological Culture Collection Center) The lactobacillus rhamnosus ZKLGG0310 is used for fermenting the dendrobium officinale extracting solution, the blood glucose reducing effect of dendrobium officinale is remarkably improved, meanwhile, lipid metabolism is adjusted, and complications of type 2 diabetes mellitus are relieved.

The invention discloses a polypeptide with DPP-IV (dipeptidyl peptidase-IV) inhibitory activity and application of the polypeptide. Pure peptides APFP and MPFP are obtained through a solid-phase synthesis method, the DPP-IV inhibition IC50 values of the pure peptides APFP and MPFP are measured to be 153.08 mu M and 296.50 mu M respectively, and the DPP-IV inhibition activity of the pure peptides APFP and MPFP is higher than that of partial fragments in the sequences of the pure peptides APFP and MPFP. The peptide fragments APFP and MPFP disclosed by the invention have relatively strong DPP-IV inhibitory activity, can be used for preparing hypoglycemic drugs or foods, and have wide application prospects in industrial application.

The invention relates to the technical field of biology, in particular to lactobacillus mucus fermentation FMBL L24016DMX capable of efficiently metabolizing pectic polysaccharides and application of the lactobacillus mucus fermentation FMBL L24016DMX, the lactobacillus mucus fermentation FMBL L24016DMX is preserved in China Center for Type Culture Collection on August 26, 2024, the preservation number is CCTCC NO: M 20241853, the lactobacillus mucus fermentation FMBL L24016DMX has good pectin metabolism capacity, pectin can be effectively used as a carbon source to achieve rapid proliferation, and the lactobacillus mucus fermentation FMBL L24016DMX can be used for efficiently metabolizing the pectin is fermented to generate a large amount of short-chain fatty acid, and meanwhile, the pectin has relatively strong scavenging capacity on DPPH and ABTS free radicals; the compound has a relatively good inhibition effect on the activity of alpha-glucosidase and alpha-amylase; the compound can be used for preparing antioxidant products, hypoglycemic drugs, fermented foods, health-care products, food additives and feeds, and has wide application prospects.

The invention discloses lactobacillus helveticus for producing DPP-IV (dipeptidyl peptidase-IV) inhibitory peptide and hypoglycemic goat milk and a preparation method thereof, goat milk is used as a raw material, and lactobacillus helveticus KD12 for producing the DPP-IV inhibitory peptide is used for fermenting the goat milk to obtain hypoglycemic lactobacillus fermented goat milk containing the DPP-IV inhibitory peptide. And drying the fermented goat milk to obtain the hypoglycemic lactic acid bacteria fermented goat milk powder containing the DPP-IV inhibitory peptide. Lactic acid bacteria of the hypoglycemic lactic acid bacteria fermented goat milk are inactivated to obtain hypoglycemic post-prebiotics goat milk, and the hypoglycemic post-prebiotics goat milk powder is obtained after the hypoglycemic post-prebiotics goat milk is concentrated and dried. The hypoglycemic goat dairy product provided by the invention has a relatively high DPP-IV inhibition rate, and can be used for inhibiting DPP-IV activity after consumers eat the hypoglycemic goat dairy product so as to reduce blood sugar and reduce the dosage of hypoglycemic drugs, so that side effects caused by the hypoglycemic drugs are reduced.

The invention discloses bifidobacterium breve with hypoglycemic capacity and application, a product and a method thereof, and belongs to the technical field of microorganisms. The invention provides a bifidobacterium breve (Bifidobacterium breve) strain BBr37 with the blood sugar reducing capacity, and the preservation number of the bifidobacterium breve strain BBr37 is CGMCC (China General Microbiological Culture Collection Center) NO.32423. The invention also provides an application of the strain BBr37 in preparation of hypoglycemic drugs or health-care foods with an auxiliary hypoglycemic function or bacteriostatic agents or non-treatment-destination bacteriostasis, and a product and a method based on the strain BBr37. The strain BBr37 disclosed by the invention has a relatively strong inhibition effect on escherichia coli, staphylococcus aureus, salmonella, haemophilus parasuis, haemophilus parainfluenza, campylobacter jejuni and enterocolitis yarrowia, and can effectively achieve the effects of reducing blood sugar and regulating intestinal flora.

The invention belongs to the field of biological pharmacy, and relates to an alpha-amylase inhibitory peptide and application thereof. Specifically, the provided unreported peptide fragment LDKFLWT can effectively inhibit the activity of alpha-amylase, and animal experiments prove that the newly designed polypeptide has the effects of reducing blood sugar, reducing blood fat, improving insulin resistance and the like through polypeptide intervention; compared with a traditional hypoglycemic drug, the alpha-amylase inhibitory peptide disclosed by the invention has remarkable safety.

The present application relates to the technical field of microbial medicine, and particularly to a preparation method and application of indole diterpenoid compounds. Specifically, the extract of plant endophytic fungus F4a after solid fermentation culture is separated and purified to obtain indole diterpenoid compounds; the plant endophytic fungus F4a is a strain with the preservation number CCTCC NO: M 2012531. The indole diterpenoid compounds provided by the present application have significant antifeedant, insecticidal and hypotensive activities, and they can be used as ideal candidate compounds of antifeedants, insecticides or hypoglycemic drugs. The compounds can be produced through fungal fermentation, and the preparation method is simple, efficient and high in product purity. The present application has good application prospect.

The invention discloses a drug-loaded hydrogel microneedle and a preparation method and application thereof, and the drug-loaded hydrogel microneedle comprises drug-loaded nanoparticles comprising a protein hypoglycemic drug loaded on a phenylboronic acid modified cationic polymer; the hydrogel microneedle is prepared from methacrylic acid chitosan modified by natural polyphenol and a diol diacrylic acid polymer, the drug-loaded nanoparticles are loaded on the hydrogel microneedle. The drug-loaded hydrogel microneedle has excellent biocompatibility, can effectively reduce inflammatory response through a triple therapy strategy of breaking a bacterial biofilm and improving oxidative stress response and hyperglycemia level of a wound surface, can be used for delivering different types of protein hypoglycemic drugs for promoting wound healing, and can be applied to the field of medical treatment through intelligent drug delivery. The repairing of blood vessels and tissues of wound surfaces is promoted, and a series of problems of poor bioavailability, poor treatment effect and the like of the existing hydrogel dressing are effectively solved.

The application discloses a preparation method of ethanol extract of Drynaria Rhizome and application thereof. The method comprises the following steps: crushing and sieving Drynaria Rhizome, adding ethanol, reflux extraction, combining filtrates, vacuum concentration and drying, and thus the ethanol extract of Drynaria Rhizome is obtained. The in-vitro alpha-glucosidase enzyme inhibition experiment shows that the ethanol extract of Drynaria Rhizome has a significant inhibitory effect on alpha-glucosidase enzyme, and the IC 50 is about 142.68 μ g / mL. Therefore, the ethanol extract of Drynaria Rhizome can be used for preparing a hypoglycemic drug, health care product or functional food, and has a wide application prospect.

The invention discloses application of metformin to improvement of crop seed germination and stress resistance, the metformin is used as a widely used hypoglycemic drug, has a cross-species conservative metabolism regulation function, can activate an antioxidant defense system of plants, maintain K < + > / Na < + > balance in the plants, and can improve the survivability of crops in saline-alkali soil. After the metformin is adopted to treat the seeds, the germination rate and the germination potential of the seeds are obviously improved, the chlorophyll content, the peroxidase content, the soluble protein content and the like of seedlings are obviously increased, the malondialdehyde content is obviously reduced, and the stress resistance is obviously enhanced. The technology is low in treatment cost, simple to operate and obvious in effect.

The invention discloses a procyanidine trimer compound, which has a chemical structure as shown in the specification. The hypoglycemic potential of the compound is evaluated through an in-vitro enzyme inhibition experiment, and the result shows that the compound has a remarkable inhibition effect on alpha-amylase, has good water solubility, is derived from natural plant resources, is clear in structure and good in safety, and has a huge application prospect in development of novel natural-source hypoglycemic drugs.

The invention discloses an abelmoschus manihot leaf extract and application thereof, and belongs to the technical field of abelmoschus manihot leaf extracts. The invention provides an application of an abelmoschus manihot leaf ethanol extract in preparation of a product for reducing blood sugar. The invention further provides application of the abelmoschus manihot leaf water extract in preparation of hair-blacking products. The invention also discloses an application of the abelmoschus manihot leaf extract in preparation of a product with antioxidant activity. According to the method, an Abelmoschus manihot leaf water extract, an Abelmoschus manihot leaf 95% ethanol extract and an Abelmoschus manihot leaf ethyl acetate extract are extracted, and the DPPH and ABTS free radical scavenging rate, the FRAP total reducing capacity and the influence of the extracts on the activity of alpha-glucosidase and tyrosinase are measured. Results show that the Abelmoschus manihot leaves have good antioxidant activity, GLE can be used as a hypoglycemic drug, and GLW can be used for developing related products for increasing melanin. The invention provides a reference basis for comprehensive development and product application of the abelmoschus manihot leaves.

The invention discloses lychee chitosan as well as an extraction method and application thereof. The lychee shell polysaccharide is successfully separated and purified from lychee shells through a series of processes such as hot water ultrasonic extraction, ethanol precipitation, deproteinization, ion exchange column chromatography and gel column chromatography. The lychee chitosan is heteropolysaccharide and comprises arabinose, galactose, glucose and galacturonic acid, and the molar mass ratio of the arabinose to the galactose to the glucose to the galacturonic acid is (27-29): (13-15): (13-15): (18-19). The lychee shell polysaccharide prepared by the method has good oil holding capacity and hygroscopicity, and due to the characteristics, the lychee shell polysaccharide can be used as a preparation auxiliary material and is widely applied to the fields of medicines, foods, health care products and cosmetics. In addition, the polysaccharide has a remarkable inhibition effect on alpha-amylase and alpha-glucosidase, and due to the characteristic, the polysaccharide has an extremely wide application prospect in the aspect of developing hypoglycemic drugs, functional foods and health-care products.

The present invention belongs to the technical field of hypoglycemic drugs, and specifically relates to a hypoglycemic pharmaceutical composition, a pharmaceutical preparation and a preparation method thereof. The hypoglycemic pharmaceutical composition and the pharmaceutical preparation comprise metformin hydrochloride, as well as a mixed granule of bitter melon extract and microcrystalline cellulose. The preparation method of the hypoglycemic pharmaceutical preparation comprises the following steps: Step 1, preparing a mixed granule of bitter melon extract and microcrystalline cellulose; Step 2, treating metformin hydrochloride and excipients for standby; Step 3, premixing the raw and auxiliary materials in Step 1 and Step 2; Step 4, sieving and sizing the powder premixed in Step 3; Step 5, adding a lubricant to the sized powder in Step 4 for total mixing; Step 6, tabletting and packaging the granules after total mixing in Step 5. By using the pharmaceutical composition or the pharmaceutical preparation of the present invention, it is possible to prevent and treat diabetes while reducing the incidence of gastrointestinal reactions caused by metformin hydrochloride.

The invention provides corn stigma polysaccharide, a preparation method thereof and application of the corn stigma polysaccharide in preparation of hypoglycemic drugs, and belongs to the technical field of plant polysaccharide extraction. The preparation method comprises the following steps: mixing corn stigma powder, ascorbic acid and water, adding pectinase into the mixed solution to carry out first enzymolysis, and adding cellulase and papain after 20-30 minutes to carry out second enzymolysis; after enzymolysis is completed, protein in enzymatic hydrolysate is removed, a corn stigma polysaccharide extracting solution is obtained, the corn stigma polysaccharide extracting solution is concentrated under reduced pressure, absolute ethyl alcohol is added for alcohol precipitation, then dialysis is conducted, and the corn stigma polysaccharide is obtained. The corn stigma polysaccharide prepared by the method has high yield, purity and hypoglycemic activity, and can be applied to preparation of hypoglycemic drugs.

The application discloses corn silk glucan, a structure formula of which is [→4)-β-D-Glcp-(1→]n, wherein n is 6-60, and a molecular weight range is 1-9.8 kDa. By extracting effective components in corn silk, an extract is obtained, the extract is precipitated by 30-90% ethanol, corn silk crude polysaccharide is obtained, and after the corn silk crude polysaccharide is dissolved, the corn silk crude polysaccharide is sequentially subjected to biological membrane dialysis, ion exchange resin column and HPLC-ELSD separation and purification, and corn silk glucan is obtained. The corn silk glucan and zeaxanthin are compounded to form a glucan compound, the glucan compound can stabilize insulin and improve the activity of the insulin in mouse islet cells, and the glucan compound has 2-5 times stronger hypoglycemic activity than that of zeaxanthin alone, and therefore, the glucan compound has important significance for researching new hypoglycemic drugs or health-care food for assisting hypoglycemia.

The present invention discloses a device for facilitating the disassembly of the needle of a hypoglycemic drug injection pen and a disassembly method thereof, belonging to the technical field of medical devices. It includes an injection pen, and the injection pen is an intelligent hypoglycemic drug injection pen, and a hypoglycemic drug injection pen cap. An aseptic disassembly device for disassembling the needle of the intelligent hypoglycemic drug injection pen is provided inside the intelligent hypoglycemic drug injection pen cap. An aseptic disinfection device for disinfecting the tip of the intelligent hypoglycemic drug injection pen and the injection site required by the human body is also provided inside the intelligent hypoglycemic drug injection pen cap. This device can uniformly and comprehensively disinfect the tip of the drug injection pen under aseptic conditions, and can, under aseptic conditions, remove the needle from the tip of the drug injection pen, avoiding the risk of the needle stabbing people during disassembly and causing bacterial infection. At the same time, it can also disinfect the injection site required by the patient, realizing the integrated design of the injection pen, the needle disassembly device, the disinfection tool and the injection pen cap.

This invention provides a mulberry leaf and wolfberry composition, comprising aqueous extracts of wolfberry, mulberry leaves, astragalus, yam, kudzu root, and green tea. This invention also provides oral preparations and food products containing this composition. Furthermore, this invention provides the application of the composition or oral preparation in the preparation of health foods that help maintain healthy blood sugar levels and hypoglycemic drugs. The composition provided by this invention has the effect of lowering blood sugar, and the selected raw materials are highly safe, have few toxic side effects, and are widely available, possessing significant market value and development prospects.